tag:www.gov.uk,2005:/government/organisations/advisory-council-on-the-misuse-of-drugsAdvisory Council on the Misuse of Drugs - Activity on °Ç¸ç³Ô¹ÏHM Government2026-05-13T12:00:07Z/government/publications/drug-use-in-ethnic-minority-groups-a-review-and-recommendations#2026-05-13T12:00:07Z2026-05-13T12:00:07ZResearch: Drug use in ethnic minority groups: a review and recommendationsThis report reviews drug use in ethnic minority groups and outlines recommendations for further data collection. /government/publications/semi-synthetic-cannabinoids-related-to-tetrahydro-cannabinol-and-cannabidiol#2026-05-11T11:00:02Z2026-05-11T11:00:02ZIndependent report: Semi-synthetic cannabinoids related to tetrahydro-cannabinol and cannabidiolACMD review into the use and harms of SSCs and THCA to identify compounds causing harm which are not captured by the current generic definition for cannabinoids.
/government/publications/acmd-annual-report-2023-to-2025#2026-05-08T15:52:19Z2026-05-08T15:52:19ZCorporate report: ACMD annual report 2023 to 2025An overview of work carried out by the Advisory Council on the Misuse of Drugs (ACMD) from January 2023 to December 2025./government/publications/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids#2026-04-30T11:36:48Z2026-04-30T11:36:48ZResearch: ACMD advice on 2-benzyl benzimidazole and piperidine benzimidazolone opioidsA review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids./government/publications/ethylbromazolam-review-of-the-evidence-on-its-use-and-harms#2026-04-14T11:00:01Z2026-04-14T11:00:01ZResearch: Ethylbromazolam: review of the evidence on its use and harmsThe report reviews the evidence on the use and harms of the novel benzodiazepine ethylbromazolam and recommends control under the Misuse of Drugs Act 1971./government/publications/members-register-of-interests#2026-03-23T16:12:00Z2026-03-23T16:12:00ZCorporate report: ACMD members' register of interestsOccupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD)./government/publications/acmd-work-programme-2026#2026-03-11T09:00:01Z2026-03-11T09:00:01ZCorrespondence: ACMD work programme 2026Letter to the the Minister for Policing and Crime from the Chair of the Advisory Council on the Misuse of Drugs (ACMD) discussing the ACMD work programme for 2026./government/publications/government-response-to-3-medicines-reports#2026-02-23T12:00:03Z2026-02-23T12:00:03ZCorrespondence: Government response to 3 medicines reportsThis response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines./government/publications/ganaxolone-acmd-advice#2026-02-23T12:00:03Z2026-02-23T12:00:03ZCorrespondence: Ganaxolone: ACMD adviceLetter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the consideration of ganaxolone. /government/publications/zuranolone-acmd-advice#2026-02-23T12:00:03Z2026-02-23T12:00:03ZCorrespondence: Zuranolone: ACMD adviceLetter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about zuranolone./government/publications/somapacitan-lonapegsomatropin-and-somatrogon-acmd-advice#2026-02-23T12:00:03Z2026-02-23T12:00:03ZCorrespondence: Somapacitan, lonapegsomatropin and somatrogon: ACMD adviceLetter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists./government/publications/acmd-review-of-the-evidence-on-the-use-and-harms-of-etomidate#2026-02-06T09:04:40Z2026-02-06T09:04:40ZIndependent report: ACMD review of the evidence on the use and harms of etomidateThe report presents a review of etomidate and structurally related compounds and subsequent recommendations regarding their classification and scheduling./government/publications/carisoprodol-review-of-the-evidence-on-its-use-and-harms#2026-02-05T00:01:04Z2026-02-05T00:01:04ZResearch: Carisoprodol: review of the evidence on its use and harmsThis report considers the use, harms and control of carisoprodol, a muscle relaxant previously prescribed in the UK to treat muscle spasms./government/news/new-members-appointed-to-acmd#2026-02-03T12:35:48Z2026-02-03T12:35:48ZNew members appointed to ACMDTwo leading experts have been appointed as members of the Advisory Council on the Misuse of Drugs./government/publications/advisory-council-on-the-misuse-of-drugs-member-biographies#2026-02-02T09:00:07Z2026-02-02T09:00:07ZTransparency data: Advisory Council on the Misuse of Drugs member biographiesBiographies of members of the Advisory Council on the Misuse of Drugs./government/publications/ketamine-an-updated-review-of-use-and-harms#2026-01-28T13:28:01Z2026-01-28T13:28:01ZResearch: Ketamine: an updated review of use and harmsFollowing a 2025 government commission, the ACMD has carried out a review of the use and harms of ketamine./government/news/acmd-announces-decision-on-the-classification-of-ketamine#2026-01-28T11:03:17Z2026-01-28T11:03:17ZACMD announces decision on the classification of ketamineThe Advisory Council on the Misuse of Drugs (ACMD) has today (28 January 2026) published its updated harms assessment of ketamine./government/publications/use-and-harms-of-xylazine-medetomidine-and-detomidine#2026-01-16T11:21:26Z2026-01-16T11:21:26ZResearch: Use and harms of xylazine, medetomidine and detomidineReview of the evidence on the use and harms of xylazine, medetomidine and detomidine./government/calls-for-evidence/drug-use-in-lgbt-communities-and-chemsex#2025-12-05T12:00:00Z2025-12-05T12:00:00ZDrug use in LGBT+ communities and chemsexThe Advisory Council on the Misuse of Drugs (ACMD) is reviewing the evidence of drug use in LGBT+ communities and in the context of chemsex in the UK. /government/news/david-wood-to-chair-advisory-council-on-the-misuse-of-drugs#2025-12-03T11:02:18Z2025-12-03T11:02:18ZDavid Wood to chair Advisory Council on the Misuse of DrugsProfessor Wood will replace Owen Bowden-Jones as chair on 1 January 2026.